Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma

Histopathology

Volumn 50, Issue 6, 2007, Pages 705-715

  Asano, N ^a,b,e   Suzuki, R ^a   Matsuo, K ^a   Kagami, Y ^a   Ishida, F ^b   Tamaru, J I ^c   Jin, G S ^d   Sato, Y ^d   Shimoyama, Y ^a   Yoshino, T ^d   Morishima, Y ^a   Nakamura, S ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cytotoxic molecules; Hodgkin's like anaplastic large cell lymphoma; Immunohistocytochemistry; Prognosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CYTOTOXIC FACTOR; GRANZYME B;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HODGKIN DISEASE; HUMANS; LYMPHOCYTES, NULL; LYMPHOMA, LARGE-CELL; MALE; MIDDLE AGED; PHENOTYPE; POLY(A)-BINDING PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REED-STERNBERG CELLS; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 34247606778     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02674.x     Document Type: Article

References (50)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994 84 1361 1392.
2. Jaffe ES, Krenacs L, Raffeld M. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann. Oncol. 1997 8 (Suppl. 2 17 24.
3. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999 17 3835 3849.
4. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod. Pathol. 2001 14 219 228.
5. Lymphoma Study Group of Japanese pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol. Int. 2000 50 696 702.
6. De Bruin PC, Kummer JA, Van der Valk P et al. Granzyme B expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associatied lymphoid tissue localization. Blood 1994 84 3785 3791.
7. Krenacs L, Smyth MJ, Bagdi E et al. The serine protease granzyme M is preferentially expressed in NK-cell, γδ T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood 2003 101 3590 3593.
8. Felgar RE, Macon WR, Kinney MC, Pasha T, Salhany KE. TIA-1 expression in lymphoid neoplasms: identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am. J. Pathol. 1997 150 1893 1900.
9. Yamashita Y, Yatabe Y, Tsuzuki T et al. Perforin and granzyme expression in cytotoxic T-cell lymphomas. Mod. Pathol. 1998 11 313 323.
10. Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003 102 4261 4269.
11. Boulland ML, Kanavaros P, Wechsler J, Casiraghi O, Gaulard P. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas. J. Pathol. 1997 183 432 439.
12. Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997 89 4501 4513.
13. Toro JR, Beaty M, Sorbara L et al. Gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch. Dermatol. 2000 136 1024 1032.
14. Toro JR, Liewehr DJ, Pabby N et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003 101 3407 3412.
15. Krenacs L, Wellmann A, Sorbara L et al. Cytotoxic cell antigen expression in anaplastic large-cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood 1997 89 980 989.
16. Foss HD, Anagnostopoulos I, Araujo I et al. Anaplastic large cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996 88 4005 4011.
17. Ichimura K, Kagami Y, Suzuki R et al. Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites. Pathol. Int. 2003 53 333 344.
18. Suzuki R, Kagami Y, Takeuchi K et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000 96 2993 3000.
19. Nakamura S, Shiota M, Nakagawa A et al. Anaplastic large cell lymphoma - a distinct molecular pathologic entity: a reappraisal with special reference to p80 (NPM/ALK) expression. Am. J. Surg. Pathol. 1997 21 1420 1432.
20. Asano N, Suzuki R, Kagami Y et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am. J. Surg. Pathol. 2005 29 1284 1293.
21. Kagami Y, Suzuki R, Taji H et al. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients. Am. J. Surg. Pathol. 1999 23 1184 1200.
22. Shibata DK, Arnheim N, Martin WJ. Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction. J. Exp. Med. 1988 167 225 230.
23. Simon M, Kind P, Kaudewitz P et al. Automated high-resolution polymerase chain reaction fragment analysis: a method for detecting T-cell receptor gamma-chain gene rearrangements in lymphoproliferative diseases. Am. J. Pathol. 1998 152 29 33.
24. Chittal SM, Delsol G. The interface of Hodgkin's disease and anaplastic large cell lymphoma. Cancer Surv. 1997 30 87 105.
25. Frizzera G. The distinction of Hodgkin's disease from anaplastic large cell lymphoma. Semin. Diagn. Pathol. 1992 9 291 296.
26. Harris NL. Hodgkin's lymphoma: classification, diagnosis, and grading. Semin. Hematol. 1999 36 220 232.
27. Leoncini L, Del Vecchio M, Kraft R. et al. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas - a continuous spectrum of malignant disorders. Am. J. Pathol. 1990 137 1047 1057.
28. Pileri S, Bocchia M, Baroni C et al. Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinicopathologic study of 69 cases. Br. J. Haematol. 1994 86 513 523.
29. Jaffe ES, Harris NL, Stein H, Jardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC Press 2001.
30. Seitz V, Hummel M, Marafioti T, Anagnostopoulos I, Assaf C, Stein H. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 2000 95 3020 3024.
31. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999 93 3913 3921.
32. Falini B, Bigerna B, Fizzotti M et al. ALK-expression defines a distinct group of T/Null lymphomas ('ALK lymphomas') with a wide morphological spectrum. Am. J. Pathol. 1998 153 875 886.
33. ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJ. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003 43 462 469.
34. Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S. Peripheral T-cell lymphomas expressing CD30 and CD15. Am. J. Surg. Pathol. 2003 27 1513 1522.
35. Stein H, Foss HD, Durkop H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000 96 3681 3695.
36. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects - a review. J. Pathol. 2003 200 4 15.
37. Quintanilla-Martinez L, Fend F, Moguel LR et al. Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am. J. Surg. Pathol. 1999 23 1233 1240.
38. Muschen M, Rajewsky K, Brauninger A et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J. Exp. Med. 2000 191 387 394.
39. Oudejans JJ, Kummer JA, Jiwa M et al. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol. 1996 148 233 240.
40. Benharroch D, Meguerian-Bedoyan Z, Lamant L et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998 91 2076 84.
41. Falini B, Pileri S, Zinzani PL et al. ALK-positive lymphoma: clinicopathological findings and outcome. Blood 1999 93 2697 2706.
42. Kinney MC, Kadin A. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am. J. Clin. Pathol. 1999 111 S56 S67.
43. Morris SW, Xue L, Ma Z, Kinney MC. ALK+CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br. J. Haematol. 2001 113 275 295.
44. Sandlund JT, Pui CH, Roberts WM et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 1994 84 2467 2471.
45. Shiota M, Nakamura S, Ichinohasama R et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ALK: a distinct clinicopathologic entity. Blood 1995 86 1954 60.
46. Ralfkiaer E, Wollf-Sneedorff A, Thomsen K, Geisler C, Vejlsgaard GL. T-cell receptor gamma delta-positive peripheral T-cell lymphomas presenting in the skin: a clinical, histological and immunophenotypic study. Exp. Dermatol. 1992 1 31 36.
47. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin. Hematol. 2003 40 175 184.
48. Tsuchiya T, Ohshima K, Karube K et al. Th1, Th2 and activated T-cell marker, and clinical prognosis in peripheral T-cell lymphoma, unspecified. Comparison with AILD, ALCL, lymphoblastic lymphoma and ATLL. Blood 2004 103 236 241.
49. Dukers DF, ten Berge RL, Oudejans JJ et al. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J. Clin. Pathol. 1999 52 129 136.
50. Bonzheim I, Geissinger E, Roth S et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004 104 3358 3360.